449 Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T cell therapy

• Julie Rytlewski,
• Leanne Peiser,
• Jerill Thorpe,
• Heidi Gillenwater,
• Ken Ogasawara,
• Yeonhee Kim,
• Diana Shpektor,
• Eniko Papp

Affiliations

Julie Rytlewski

Bristol Myers Squibb, Seattle, Washington, USA

Leanne Peiser

Bristol Myers Squibb, Seattle, WA, USA

Jerill Thorpe

Bristol Myers Squibb, Seattle, WA, USA

Heidi Gillenwater

Bristol Myers Squibb, Seattle, WA, USA

Ken Ogasawara

Bristol Myers Squibb, Seattle, WA, USA

Yeonhee Kim

Bristol Myers Squibb, Seattle, WA, USA

Diana Shpektor

Bristol Myers Squibb, Seattle, WA, USA

Eniko Papp

Bristol Myers Squibb, Seattle, WA, USA